Study of AZD8931 in Patients With Advanced Solid Malignancies
A Phase 1, Open-label, Multiple-dose, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8931 in Patients With Advanced Solid Malignancies
Sponsor: AstraZeneca
A PHASE1 clinical study on Advanced Solid Malignancies, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Feb 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .